Céline Tard - Concepedia

Author

Céline Tard

Also Known As

Blaž Koritnik, C Tard, C. Tard, Celine Tard, Clémence Simonin, Céline TARD, Céline Tard, Frederic Taithe, Nadjib Taouagh, Tard, Celine

226

Publications

3.8K

Citations

H-Index

107

Concepts

All Affiliations

Université de Lille Inserm Centre Hospitalier Universitaire de Lille Sorbonne Université Assistance Publique – Hôpitaux de Paris

About

Céline Tard is an author at Université de Lille specializing in medicine, health sciences, and motor control.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	23	1.7K
2	Health Sciences	13	13	421
3	Social Sciences	8	8	267
4	Public Health	3	3	65
5	Allergy	2	2	130

Céline Tard

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes Ophélie Rouxel, Jennifer Da Silva, Lucie Beaudoin, Nature Immunology InflammationType 1Autoimmune DiseaseMucosal ImmunologyT-regulatory Cell	2017	245
Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies Karim Wahbi, Rabah Ben Yaou, Estelle Gandjbakhch, Circulation	2019	245
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study James F. Howard, Saskia Bresch, Angela Genge, The Lancet Neurology MedicineSurgeryClinical TrialsGeneralised Myasthenia Gravis	2023	213
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf, The Lancet Neurology Late-onset Pompe DiseaseAutoimmune DiseaseClinical Infectious DiseaseMedicinePhase 3	2021	169
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study David Adams, Michael Polydefkis, Alejandra González‐Duarte, The Lancet Neurology Alzheimer's DiseaseOpen-label Extension StudyMedicineHereditary Transthyretin-mediated AmyloidosisNeurology	2020	154
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial Benedikt Schoser, Mark Roberts, Barry J. Byrne, The Lancet Neurology Clinical TrialsCipaglucosidase AlfaPharmacotherapyMedicineLate-onset Pompe Disease	2021	124
Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera Émilien Delmont, Alexandre Brodovitch, Ludivine Kouton, Journal of Neurology RheumatologyMedical DiagnosticsAllergyLupusDiagnostic Test	2020	103
Auditory cueing of gait initiation in Parkinson’s disease patients with freezing of gait Arnaud Delval, Caroline Moreau, S. Bleuse, Clinical Neurophysiology KinesiologyAuditory CueingAuditory PhysiologyMotor ControlRehabilitation	2014	93
Motor neuron pathology in CANVAS due to <i>RFC1</i> expansions Vincent Huin, Giulia Coarelli, Clément Guemy, Brain Motor Control DisordersCorticobasal DegenerationNeurological DisorderMotor ControlRfc1 Biallelic Expansions	2021	71
The pattern of attentional deficits in Parkinson's disease Kathy Dujardin, Céline Tard, Alain Duhamel, Parkinsonism & Related Disorders Brain FunctionMedicineParkinson DiseaseAttentional DeficitsNeurology	2012	65

Page 1